Aquinnah Pharmaceuticals Receives $10 Million Investment from Pfizer and AbbVie to Research Breakthrough Approach to Neurodegene...
CAMBRIDGE, Mass., April 25, 2017 /PRNewswire/ -- Aquinnah Pharmaceuticals, a privately held biotechnology company focused on RNA binding proteins for neurodegenerative disease, announced today that two additional pharmaceutical companies, Pfizer Inc. (NYSE: PFE) and AbbVie Inc. (NYSE: ABBV), have invested in Aquinnah's work to treat ALS (Amyotrophic Lateral Sclerosis), Alzheimer's disease and other neurodegenerative diseases. This $10 million adds to an earlier $5 million investment made by Takeda Pharmaceuticals in December 2015.http://prn.to/2pz7gZ2